Free shipping on all orders over $ 500

 About 7 results found for searched term "83-49-8" (0.125 seconds)

Cat.No.  Name Target
M11414 Hyodeoxycholic acid Metabolite/Endogenous Metabolite
HDCA; NSC 60672
Hyodeoxycholic acid is a secondary bile acid formed by intestinal flora in the small intestine and is an agonist of TGR5 (GPCR19). In CHO cells, the EC50 value is 31.6 µM.
M17889 2,3-Dimethoxyxanthone Xanthones
2,3-Dimethoxyxanthone
M10475 Lifirafenib (BGB-283) Raf
Beigene-283
Lifirafenib (BGB-283) is a novel potent and selective RAF Kinase and EGFR inhibitor with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant.
M13452 MMAF-OMe Others
Monomethyl auristatin F methyl ester
MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4-) cell lines, respectively.
M20633 TP0427736 HCl Src-bcr-Abl
TP0427736 is a potent inhibitor of ALK5 kinase activity with an IC50 of 2.72 nM and this effect is 300-fold higher than the inhibitory effect on ALK3 (IC50 = 836 nM for ALK3). It also inhibits Smad2/3 phosphorylation in A549 cells induced by TGF-β1 with an IC50 value of 8.68 nM.
M28062 PF-4950834  ROCK
PF-4950834 is a potent, selective, orally bioavailable, ATP-competitive rho kinase inhibitor with IC50 values of 8.35 nM and 33.12 nM against ROCK2 and ROCK1, respectively. PF-4950834 inhibits neutrophil migration.
M28252 GSK837149A  FAS
GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (Ki=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.